A Novel EGFRvIII-T Cell Bispecific Antibody for the Treatment of Glioblastoma

Scientists designed and developed a novel 2+1 EGFRvIII-TCB with optimal pharmacological characteristics and potent anti-tumor activity.
[Molecular Cancer Therapeutics]
Abstract
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News